SIGNAL GRIDv0.1

Lilly sets up next-gen obesity battle with full phase 3 retatrutide data - Fierce Biotech

1 sources1 storiesFirst seen 9/30/2026Score32Mixed Progress
Single Source
CoverageRecencyEngagementVelocityBignessConfidenceClipability
Bigness
32
Coverage
13
Recency
93
Engagement
19
Velocity
0
Confidence
50
Clipability
55
Polarization
0
Claims
3
Contradictions
0
Breakthrough
50

Sentiment Mix

Positive0%
Neutral100%
Negative0%

Expert Signals

Politics - Google News US Headlines

source • 1 mention

AI-Generated Claims

Generated from linked receipts; click sources for full context.

Lilly sets up next-gen obesity battle with full phase 3 retatrutide data - Fierce Biotech.

Supported by 1 story

Lilly sets up next-gen obesity battle with full phase 3 retatrutide data Fierce BiotechEli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Supported by 1 story

tirzepatide 15 mg in adults with obesity and type 2 diabetes Eli Lilly‘Godzilla' of weight-loss drugs could provide other important health benefits The Guardian

Supported by 1 story

Related Events

Timeline (1 stories)

Receipts (1)

Bias Snapshot

Center
Left 0%Center 100%Right 0%
Blognews.google.com9/30/2026